Dr. Hope on Benefits of Gallium 68-Dotatate PET Scan

Video

In Partnership With:

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the Gallium 68-Dotatate PET scan in the imaging of neuroendocrine tumors (NETs).

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the Gallium 68-Dotatate PET scan in the imaging of neuroendocrine tumors (NETs).

Imaging for NETs is difficult as they are slow growing, requiring very sensitive imaging studies. Commonly, the octreoscan has been used in practice to track these tumors, which targets somatostatin receptors.

Recently, the Gallium-68 dotatate scan that is labeled with Gallium-68, a radionuclide, has demonstrated much higher sensitivity for both detection and characterization of NETs.

While the cost is high, the benefits outweigh this, says Hope. Octreoscan takes a minimum 1 2 days to complete, while a Gallium-68 dotatate scan takes about 1 hour to conduct after injection. Also, the improved imaging allows physicians to more accurately track patients over time.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Related Content
Elliot Stieglitz, MD

Targeted Treatment of Rare Childhood Leukemia

March 29th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Hope S. Rugo, MD, FASCO, of University of California, San Francisco

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

March 8th 2024
Article
Hyunseok (Hyu) Kang, MD, MPH, FACP, associate professor, medical oncologist, the University of California, San Francisco Health

Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice

February 29th 2024
Podcast
Kole Roybal, PhD, associate professor, microbiology and immunology, UC San Francisco

In Judo Move, Scientists Use Cancer’s Strength to Fight Against It

February 23rd 2024
Article
Sanket Dhruva, MD, MHS, assistant professor, medicine, the University of California San Francisco

Are Higher Standards for Expedited FDA Approvals Needed?

February 15th 2024
Article